Peginterferon alfa-2b Treatment for Patients Affected by Acute Hepatitis C: Presentation of Six Case Reports |
| |
Authors: | Email author" target="_blank">G?ScottoEmail author E?Palumbo V?Fazio D?C?Cibelli A?Saracino G?Angarano |
| |
Institution: | (1) Infectious Diseases Clinic, University of Foggia, Italy, Via L. Pinto 1, I-71100 Foggia, Italy;(2) Infectious Diseases Clinic, University of Foggia, Italy;(3) Laboratory Dept., Hospital of Foggia, Italy |
| |
Abstract: | Abstract
Acute hepatitis C often progresses to chronic infection (70%). In this clinical study, we evaluated if early treatment with peginterferon alfa-2b can prevent acute hepatitis C from developing into a chronic disease. Six patients with acute hepatitis C, based on a well-documented hepatitis C virus (HCV) seroconversion with high alanine aminotransferase (ALT) levels (> 10 x ULN) and persistent HCV RNA titers after 3 months from disease onset, were consecutively treated with peginterferon alfa-2b at 1.5 µg/kg/weekly/sc for 24 weeks. The viral load was quantified by PCR assay. Response was defined as undetectable HCV RNA and normal ALT levels at the end of therapy and after a 6-month follow-up. All patients completed therapy; at the end of therapy, 5/6 patients (83%) responded and no relapses were observed during follow-up. No correlation was found between treatment response and pretreatment viral load, viral genotype, and interval between acute infection diagnosis and start of therapy. |
| |
Keywords: | |
本文献已被 PubMed SpringerLink 等数据库收录! |
|